<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002291</url>
  </required_header>
  <id_info>
    <org_study_id>022A</org_study_id>
    <secondary_id>87-71</secondary_id>
    <nct_id>NCT00002291</nct_id>
  </id_info>
  <brief_title>The Safety and Effectiveness of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS Who Have Had PCP Before</brief_title>
  <official_title>A Double-Blind Group Comparative Study To Evaluate the Safety and Effectiveness of Three Different Doses of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in Patients With AIDS Post First Episode PCP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fisons</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate and compare the safety, tolerability, and efficacy of biweekly administration of
      1 of 3 doses of aerosol pentamidine when used as a prophylactic agent in patients who have
      recovered from their first episode of AIDS-associated Pneumocystis carinii pneumonia (PCP).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Pneumonia, Pneumocystis Carinii</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentamidine isethionate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Zidovudine (AZT).

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following are excluded:

          -  Requiring ongoing active therapy for an opportunistic infection (O.I.) at time of
             entry or those with either of the following AIDS-defining O.I.'s prior to entry:

          -  Toxoplasmosis.

          -  Cryptococcosis.

          -  Transfusion dependent (requiring blood transfusion more than once per month). The last
             transfusion cannot have been given within 7 days of study entry.

          -  Pulmonary Kaposi's sarcoma (KS).

          -  Asthma requiring medication.

          -  Active therapy for tuberculosis.

        Concurrent Medication:

        Excluded:

          -  Active therapy for tuberculosis.

        Patients with the following are excluded:

          -  Requiring ongoing active therapy for an opportunistic infection (O.I.) at time of
             entry or those with either of the following AIDS-defining O.I.'s prior to entry:

          -  Toxoplasmosis.

          -  Cryptococcosis.

          -  Transfusion dependent (requiring blood transfusion more than once per month). The last
             transfusion cannot have been given within 7 days of study entry.

          -  Pulmonary Kaposi's sarcoma (KS).

          -  Unwilling to sign informed consent.

          -  Cannot cooperate with study procedures.

          -  Asthma requiring medication.

        Prior Medication:

        Excluded within 30 days of study entry:

          -  Antiretrovirals other than zidovudine (AZT).

          -  Immunomodulating agents.

          -  Corticosteroids.

        Patients must:

          -  Have AIDS and recovered from their first episode of cytologically or histologically
             proven Pneumocystis carinii pneumonia (PCP).

          -  Be at least 2 weeks and no more than 24 weeks status post therapy for acute PCP.

          -  Have positive antibody to HIV by any federally licensed ELISA test kit, or confirmed
             Western blot test.

          -  Have adequate pulmonary function (vital capacity = or &gt; 80 percent of predicted;
             forced expiratory volume (FEV), 1 s = or &gt; 65 percent of total FEV; and corrected
             pulmonary diffusion capacity &gt; 60 percent of predicted).

          -  Free of acute medical problems.

        Active substance abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fisons Corp</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Murphy RL, Lavelle JP, Allan JD, Gordin FM, Dupliss R, Boswell SL, Waskin HA, Davies SF, Graziano FM, Saag MS, et al. Aerosol pentamidine prophylaxis following Pneumocystis carinii pneumonia in AIDS patients: results of a blinded dose-comparison study using an ultrasonic nebulizer. Am J Med. 1991 Apr;90(4):418-26.</citation>
    <PMID>2012082</PMID>
  </reference>
  <verification_date>October 1989</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Pneumonia, Pneumocystis carinii</keyword>
  <keyword>Pentamidine</keyword>
  <keyword>Dose-Response Relationship, Drug</keyword>
  <keyword>Aerosols</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Pneumocystis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentamidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

